HC Wainwright Issues Positive Forecast for Dynavax Technologies (NASDAQ:DVAX) Stock Price

Dynavax Technologies (NASDAQ:DVAX) had its target price increased by HC Wainwright from $29.00 to $31.00 in a research report released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Dynavax Technologies’ Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.12 EPS, FY2025 earnings at $0.35 EPS and FY2026 earnings at $0.45 EPS.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $12.39 on Tuesday. The company has a market capitalization of $1.63 billion, a P/E ratio of 95.32 and a beta of 1.34. The company’s 50-day moving average is $12.78 and its 200 day moving average is $11.66. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. Dynavax Technologies has a fifty-two week low of $9.74 and a fifty-two week high of $14.30.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of DVAX. Assenagon Asset Management S.A. purchased a new position in Dynavax Technologies in the third quarter valued at approximately $8,291,000. Entropy Technologies LP purchased a new position in shares of Dynavax Technologies during the 3rd quarter valued at $462,000. Nordea Investment Management AB lifted its position in shares of Dynavax Technologies by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock valued at $10,034,000 after buying an additional 232,690 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Dynavax Technologies by 8.3% during the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after acquiring an additional 82,449 shares during the period. Finally, Millennium Management LLC purchased a new stake in Dynavax Technologies in the 2nd quarter worth about $17,615,000. 96.96% of the stock is owned by institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.